The Diet That Invented Group Therapy Now Writes Prescriptions
It taught a generation to count points and lean on each other. Then a weekly shot changed the math - so WeightWatchers went to the doctor.
In 1961, a 38-year-old bookkeeper in Queens named Jean Nidetch was mortified when a neighbor mistook her weight for a pregnancy. She started a diet from the New York City Board of Health, but the diet was not the interesting part. The interesting part was that she invited six friends into her living room every week to weigh in, confess, and cheer. Within two months, 40 women were crowding in. Two years later, in 1963, that gathering became a company. Six decades on, it is trying to survive the single biggest change to weight loss since the calorie chart - and it is doing it by selling the very thing that nearly ended it.
WeightWatchers - legally WW International, Inc. - built a durable business on a plain idea: people lose more weight with structure and support than they do alone. The company translated that into a food system, a weekly meeting, a membership fee, and eventually an app. For most of its life, that was enough to make it the most recognizable name in dieting and, by its own description, the most clinically studied commercial provider of weight-management services. Then a class of drugs arrived that could do in a month what workshops took a year to coax out of willpower.
01 / What it doesA points system, a meeting, and now a clinic
At its core WeightWatchers sells behavior change as a subscription. Its longtime engine is the Points program, which assigns every food a single number based on its nutrition and hands each member a personalized daily Points Budget. To nudge people toward better defaults, more than 150 ZeroPoint foods - most fruits, vegetables and lean proteins - don't have to be tracked at all. The whole thing lives in the WeightWatchers app, which now includes an AI-assisted food scanner that reads barcodes and photos, a recipe importer that calculates Points from any website, and progress tracking.
Wrapped around the food system is the part that predates the app by half a century: coaching and community. Workshops, in person and virtual, are the direct descendants of Nidetch's living room. And since 2023, the newest limb - WeightWatchers Clinic - connects eligible members to board-certified clinicians who can prescribe GLP-1 medications such as Wegovy and Zepbound. Points, people, and prescriptions now sit inside one brand.
02 / Who it servesThe audience that grew up, and the one taking the shot
For most of its history the membership skewed female and middle-aged - people who wanted a plan and a room full of others chasing the same goal. That base is still large, but it is shrinking and shifting. Membership fell from about 4.9 million in 2021 to roughly 3.6 million in 2024, and three out of four remaining members never attend a workshop at all. Meanwhile a new customer appeared: the person seeking, or already taking, a weight-loss drug, and looking for a trustworthy place to get it prescribed and managed.
03 / The problem it solvesKeeping weight off is harder than losing it
Losing weight is a moment; keeping it off is a decade. That gap is the problem WeightWatchers has always aimed at - the follow-through that diets promise and few deliver. Its bet is that structure, tracking and accountability outlast motivation. In the drug era that argument has actually sharpened: GLP-1 medications are powerful, but they work best alongside changes in eating and habit, and people who stop taking them often regain weight. A company built on sustainable behavior suddenly had a reason to exist next to the pharmacy, not against it.
04 / How it's differentSixty years of data, and a room full of people
The new wave of competitors - Noom, Hims & Hers, Ro, Found, Calibrate - are mostly telehealth-native, born in the app-store era and often organized around a prescription pad. WeightWatchers is coming from the other direction: it already owns the behavioral engine, the coaching, the community, and a name people's parents trusted. Its distinct claim is depth of evidence and the human layer around the medicine - registered dietitians, workshops, and decades of published research on the habits that make weight loss stick. Where rivals bolt behavior onto a drug business, WeightWatchers is bolting a drug business onto behavior.
05 / The business modelRecurring revenue, rebuilt around care
The money comes largely from subscriptions: monthly fees for digital access to the app and Points program, for workshops, and - through WeightWatchers Clinic - for telehealth visits and medication management. Historically the company also earned from branded and licensed foods. Revenue has come down with the membership, landing somewhere around $870 million to $1.1 billion depending on the measure and year, off a 2018 peak near $1.5 billion. The strategic shift is where the growth is now pointed: the clinical segment, not the classic workshop, is the engine management is feeding.
06 / The expertiseDietitians, coaches, and now clinicians
What WeightWatchers has that a fresh startup can't buy quickly is accumulated behavioral knowledge - the science of nudges, ZeroPoint defaults, tracking that people will actually keep up with, and coaches trained to run a room. The 2023 acquisition of the telehealth company Sequence, for about $132 million, grafted a second kind of expertise onto that base: board-certified clinicians and the infrastructure to prescribe and monitor medication. The company is, in effect, trying to hold two disciplines at once - habit and pharmacology.
07 / Where it sits in the marketThe incumbent that refused to fade quietly
WeightWatchers occupies an unusual seat: the legacy giant of a category being rewritten in real time. It is the household name in a field suddenly crowded with telehealth challengers and direct-to-consumer pharmacies. Its advantage is trust and reach; its risk is that the very drugs reshaping the market are cheaper and faster than a subscription to a points app. The whole 2025 restructuring - the bankruptcy, the debt cut, the clinical relaunch, the new CEO - reads as an incumbent deciding it would rather cannibalize itself than be cannibalized.
That reinvention has a human backdrop. Oprah Winfrey, who bought roughly 10% of the company in 2015 and became its most famous member, left the board in early 2024 after disclosing she used a weight-loss medication; the stock fell about 25% in a day. CEO Sima Sistani, who led the pivot into drugs, departed in late 2024. In her place came Tara Comonte - a former president and CFO of Shake Shack and CEO of TMRW Life Sciences - who took the top job in 2025 and steered the company through Chapter 11.
- 1963 — A Queens living-room support group becomes a company.
- 1968 — First IPO as Weight Watchers International.
- 1978 — H.J. Heinz buys it for about $72 million.
- 2015 — Oprah Winfrey takes ~10% and joins the board.
- 2018 — Rebrands from Weight Watchers to WW.
- 2023 — Acquires Sequence; can now prescribe GLP-1 drugs.
- 2025 — 42-day Chapter 11 cuts ~$1.15B of debt; relaunches around the clinic.
Whether the gamble works is an open question. The behavioral thesis that Jean Nidetch stumbled into in her living room - that accountability and company make change stick - is exactly the thing the drug era is testing. WeightWatchers is betting that when the injections do the heavy lifting, someone still has to teach people how to eat, and that after 60 years, it's the name people will trust to do it.